Allspring Global Investments Holdings LLC grew its holdings in abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 16.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 193,484 shares of the company's stock after buying an additional 27,433 shares during the period. Allspring Global Investments Holdings LLC owned 0.67% of abrdn Life Sciences Investors worth $2,455,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the business. Commonwealth Equity Services LLC increased its stake in shares of abrdn Life Sciences Investors by 3.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 30,119 shares of the company's stock worth $395,000 after purchasing an additional 933 shares during the period. 180 Wealth Advisors LLC boosted its holdings in shares of abrdn Life Sciences Investors by 0.9% during the 1st quarter. 180 Wealth Advisors LLC now owns 136,122 shares of the company's stock valued at $1,727,000 after acquiring an additional 1,247 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in abrdn Life Sciences Investors by 379.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company's stock worth $64,000 after buying an additional 3,847 shares during the period. Oppenheimer & Co. Inc. lifted its holdings in abrdn Life Sciences Investors by 46.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 28,713 shares of the company's stock worth $364,000 after buying an additional 9,115 shares during the period. Finally, Wealthcare Advisory Partners LLC bought a new position in shares of abrdn Life Sciences Investors in the 1st quarter worth about $131,000. 32.21% of the stock is owned by institutional investors and hedge funds.
abrdn Life Sciences Investors Stock Performance
abrdn Life Sciences Investors stock traded up $0.14 during midday trading on Thursday, reaching $13.39. The stock had a trading volume of 120,235 shares, compared to its average volume of 107,901. abrdn Life Sciences Investors has a 12 month low of $10.55 and a 12 month high of $15.90. The company has a fifty day moving average price of $12.61 and a two-hundred day moving average price of $12.93.
abrdn Life Sciences Investors Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Thursday, May 22nd were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 12.85%. The ex-dividend date of this dividend was Thursday, May 22nd.
Insider Transactions at abrdn Life Sciences Investors
In other abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 23,729 shares of abrdn Life Sciences Investors stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $12.08, for a total transaction of $286,646.32. Following the completion of the transaction, the insider owned 3,028,958 shares in the company, valued at approximately $36,589,812.64. The trade was a 0.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 62,388 shares of company stock worth $752,056. 10.06% of the stock is currently owned by insiders.
About abrdn Life Sciences Investors
(
Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Further Reading
Before you consider abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and abrdn Life Sciences Investors wasn't on the list.
While abrdn Life Sciences Investors currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
